CUSIP: 29970R105
Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / ADS
-
Total 13F shares
-
678,270
-
Share change
-
-399,144
-
Total reported value
-
$2,060,000
-
Put/Call ratio
-
3.6%
-
Price per share
-
$3.05
-
Number of holders
-
11
-
Value change
-
-$1,258,575
-
Number of buys
-
6
-
Number of sells
-
7
Quarterly Holders Quick Answers
What is CUSIP 29970R105?
CUSIP 29970R105 identifies EVAX - EVAXION BIOTECH A S - ADS in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2022
-
Previous quarter:
Q4 2021
Recent filing periods for CUSIP 29970R105:
Institutional Holders of EVAXION BIOTECH A S - ADS (EVAX) as of Q1 2022
As of 31 Mar 2022,
EVAXION BIOTECH A S - ADS (EVAX) was held by
11 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
678,270 shares.
The largest 10 holders included
LUMINUS MANAGEMENT LLC, Telemetry Investments, L.L.C., Kepos Capital LP, TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC, MORGAN STANLEY, ETF MANAGERS GROUP, LLC, CITIGROUP INC, UBS Group AG, and Steward Partners Investment Advisory, LLC.
This page lists
11
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.